Fos-related antigen-1 (Fra-1) is a regulator of glioma cell malignant phenotype

Cancer Biology and Therapy

Volumn 11, Issue 3, 2011, Pages 307-310

  Kesari, Santosh ^a   Bota, Daniela A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activating protein 1 (AP 1); Fos related antigen 1 (Fra 1); JunB; Malignant gliomas; Migration

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 3; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BEVACIZUMAB; CAMPTOTHECIN; CISPLATIN; CYCLIN A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GELATINASE B; INTERLEUKIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN V FOS; RAS PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR JUNB; UNINDEXED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

CARCINOGENESIS; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HEART ATRIOVENTRICULAR NODE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NOTE; ONCOGENE C JUN; OSTEOPENIA; PHENOTYPE; UTERINE CERVIX CANCER;

GENE SILENCING; GENES, JUN; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION FACTOR AP-1;

EID: 79951533078     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.3.14718     Document Type: Note

References (41)

1. Primary Brain Tumors in the United States. Statistical Report 1997-2001. Central Brain Tumor Registry of the United States 2004-2005.
2. Karin M, Liu Zg, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9:240-6. (Pubitemid 27135992)
3. Hai T, Curran T Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 1991; 88:3720-4. (Pubitemid 21916695)
4. De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 1995; 11:365-76.
5. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072:129-57.
6. Colotta F, Polentarutti N, Sironi M, Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 1992; 267:18278-83.
7. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20:2401-12. (Pubitemid 32531298)
8. Huang C, Schmid PC, Ma WY, Schmid HH, Dong Z. Phosphatidylinositol-3- kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J Biol Chem 1997; 272:4187-94. (Pubitemid 27078486)
9. Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002; 21:5038-46.
10. Potapova O, Gorospe M, Bost F, Dean NM, Gaarde WA, Mercola D, et al. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 2000; 275:24767-75. (Pubitemid 30626580)
11. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA, Holbrook NJ. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 2000; 20:1713-22. (Pubitemid 30100190)
12. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313:144-7 (Pubitemid 15192341)
13. Goussia AC, Agnantis NJ, Rao JS, Kyritsis AP. Cytogenetic and molecular abnormalities in astrocytic gliomas (Review). Oncol Rep 2000; 7:401-12.
14. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355:846-7
15. Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, et al. PTEN downregulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway. Mol Cell Biochem 2007; 300:77-87 (Pubitemid 46881818)
16. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 2007; 102:522-38. (Pubitemid 47000605)
17. Tulchinsky E. Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol 2000; 15:921-8. (Pubitemid 30488571)
18. Risse-Hackl G, Adamkiewicz J, Wimmel A, Schuermann M. Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins. Oncogene 1998; 16:3057-68. (Pubitemid 28297728)
19. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96:1603-8. (Pubitemid 29098498)
20. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41:2449-61. (Pubitemid 41540622)
21. Schreiber M, Wang ZQ, Jochum W, Fetka I, Elliott C, Wagner EF. Placental vascularisation requires the AP-1 component fra1. Development 2000; 127:4937-48.
22. Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 2004; 23:2789-99. (Pubitemid 39013551)
23. Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr, Matsuo K, et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 2000; 6:980-4.
24. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3:859-68. (Pubitemid 37383716)
25. Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 2005; 3:237-49. (Pubitemid 40525334)
26. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48:347-56.
27. Plate KH, Breier G, Weich HA, Risau W Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359:845-8.
28. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999; 84:10-8. (Pubitemid 29059101)
29. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55:1189-93.
30. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116:3988-99.
31. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95:548-53.
32. Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, et al. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol Med 2001; 7:598-608. (Pubitemid 34175288)
33. Schorpp-Kistner M, Wang ZQ, Angel P, Wagner EF. JunB is essential for mammalian placentation. EMBO J 1999; 18:934-48. (Pubitemid 29082273)
34. Choo KB, Huang CJ, Chen CM, Han CP, Au LC. Jun-B oncogene aberrations in cervical cancer cell lines. Cancer Lett 1995; 93:249-53.
35. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003; 101:1513-9. (Pubitemid 36182528)
36. Deng T, Karin M. JunB differs from c-Jun in its DNA-binding and dimerization domains and represses c-Jun by formation of inactive heterodimers. Genes Dev 1993; 7:479-90. (Pubitemid 23139240)
37. Konishi N, Shimada K, Nakamura M, Ishida E, Ota I, Tanaka N, et al. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer. Clin Cancer Res 2008; 14:4408-16.
38. + cells. Mol Carcinog 2008; 47:485-91.
39. Ehret A, Li-Weber M, Frank R, Krammer PH. The effect of HIV-1 regulatory proteins on cellular genes: derepression of the IL-2 promoter by Tat. Eur J Immunol 2001; 31:1790-9. (Pubitemid 32547342)
40. Casalino L, Bakiri L, Talotta F, Weitzman JB, Fusco A, Yaniv M, et al. Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J 2007; 26:1878-90. (Pubitemid 46624039)
41. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 2006; 8:58-70. (Pubitemid 43154265)